Abstract
Introduction: Glaucoma is a progressive and chronic optic neuropathy being the second cause of irreversible blindness worldwide. Several approaches are used to try to avoid this course, being the Trabeculectomy the surgical choice in the adult patient.
Objetive: To analyze a cohort of patients that had trabeculectomy between 2005 and 2011 in San Ignacio’s University Hospital.
Conclusion: Although is a small cohort of patients it enables us to confirm that this surgery is a good choice in the control of the intraocular pressure in order to avoid further damage to the optic nerve.
Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-93.
Kass MA, Heder DK, Higginbotham EJ et al. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120(6):701-13.
Chang L, Crowston JG, Cordeiro F et al. The role of the immune system in conjunctival wound healing alter glaucoma surgery. Surv Ophthalmol. 2000;45(1): 49-68.
The Fluorouracil Filtering Surgery Study group. Fluorouracil filtering surgery study one year follow up. Am J Ophthalmol. 1989;108(6):625-35.
Chen CW, Huang HT, Bair JS, Lee CC. Trabeculectomy with simultaneous topical application of mitomycin C in refractory glaucoma. J Ocul Pharmacol. 1990;6(3):175-82.
Cairns JE. Trabeculectomy: preliminary report of a new method. Am J Ophthalmol. 1968;66:673-9.
Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology. 1991;98:317-21.
Singh K, Egert PR, Byrd S et al. Trabeculectomy with intraoperative 5-fluoruracil vs mitomycin C. Am J Ophthalmol. 1997;123:48-53.
Moorthy RS, Mermoud A, Baervelt G et al. Glaucoma associated with uveitis. Surv Ophthalmol. 1997;41:361.
Goldenfeld M, Krupin T, Ruderman JM et al. 5 Fluorouracil in inicial trabeculectomy. A prospective, randomized multicenter study. Ophthalmology. 1994;101(6):1024-9.
Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication in the conjunctival cell profile. Arch Ophthalmol. 1991;112;1137-45.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.